Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial.
- DOI
- 10.1136/bjo-2024-326526
- Published
- 2025 Dec 15
- Container
- The British journal of ophthalmology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bjo-2024-326526,
title = {Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial.},
author = {Agostini HT and Silva R and Holz FG and Larsen M and Altay L and Souied EH and Quiering C and Rose U and Liakopoulos S and SALT study group},
year = {2025},
journal = {The British journal of ophthalmology},
doi = {10.1136/bjo-2024-326526},
url = {https://doi.org/10.1136/bjo-2024-326526}
}RIS
TY - JOUR TI - Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial. AU - Agostini HT AU - Silva R AU - Holz FG AU - Larsen M AU - Altay L AU - Souied EH AU - Quiering C AU - Rose U AU - Liakopoulos S AU - SALT study group PY - 2025 JO - The British journal of ophthalmology DO - 10.1136/bjo-2024-326526 UR - https://doi.org/10.1136/bjo-2024-326526 ER -
APA
HT, A., R, S., FG, H., M, L., L, A., EH, S., C, Q., U, R., S, L., & group, S. S. (2025). Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial.. The British journal of ophthalmology. https://doi.org/10.1136/bjo-2024-326526
Source records
- pubmed · retrieved 2026-09-25T18:13:41.646Z